© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Social Determinants of Health Affect Use of HRT During Menopause, Study Suggests
June 04, 2025
Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.
Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
June 04, 2025
Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose
June 04, 2025
Your daily dose of the clinical news you may have missed.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
June 03, 2025
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia
June 03, 2025
A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.
OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer
June 03, 2025
ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission
June 03, 2025
Nasus Pharma says promising phase 2 results for FMXIN002 show statistically significantly faster absorption than traditional autoinjectors and are published in global journal.
Novel Resorbable Sinonasal Implant Significantly Reduces Symptoms in Treatment-Resistant CRS
June 03, 2025
Lyra Pharmaceuticals designed the implant, which provides 6 months of continuous delivery of the anti-inflammatory mometasone furoate.
New-Onset T2D Tied to Higher Risk of Obesity-Related Cancer: Daily Dose
June 03, 2025
Your daily dose of the clinical news you may have missed.
New Data on Atopic Dermatitis for Frontline Clinicians: RAD 2025 Preview
June 02, 2025
Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.